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Abstract
Background: Irritable Bowel Syndrome (IBS) is a functional somatic syndrome characterized by patterns of
persistent bodily complaints for which a thorough diagnostic workup does not reveal adequate explanatory
structural pathology. Detailed insight into disease-specific health-care costs is critical because it co-determines the
societal impact of the disease, enables the assessment of cost-effectiveness of existing and new treatments, and
facilitates choices in treatment policy. In the present study the aim was, to compare the costs and magnitude of
healthcare consumption for patients diagnosed with Irritable Bowel Syndrome (IBS) in primary and secondary care,
compare these costs with the average health care expenditure for patients without IBS and describe these costs in
further detail.
Methods: Reimbursement data for patients diagnosed with IBS by a general practitioner (GP) or specialist between
2006 and 2009 were extracted from a healthcare insurance company and compared to an age and gender
matched control group of patients without IBS. Using a case-control design, direct medical costs for GP
consultations, specialist care and medication prescriptions were calculated.
Results: Data of 326 primary care and 9274 secondary care IBS patients were included in the analysis. For primary
care patients, the mean total annual health care costs for the three years after diagnosis compared to the three
years before diagnosis, increased with 486 Euro after IBS was diagnosed, whereas for secondary care patients, these
costs increased with 2328 Euro. Total health care costs remained higher in the three years after the initial diagnosis
when the patient is treated in secondary care, compared to primary care. This increase was significant for hospital
specialist costs and medications, but not for GP contacts. For controls, there was no significant difference in mean
total annual health costs in the three years before and the three years after the diagnosis and also no significant
difference in cost increases between both primary- and secondary-care control patients.
Conclusion: Total healthcare costs per patient substantially increase after a diagnosis of IBS and IBS related costs
are significantly higher when patients are treated in secondary-care compared to primary-care. IBS patients should
be treated in primary-care where possible, not only because guidelines recommend this from a quality of care
viewpoint, but also to optimize use of health care resources. Referral should be restricted to those patients with
alarm symptoms, with ill-matching symptoms, or other cases of diagnostic uncertainty.
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Background
Irritable bowel syndrome (IBS) is a functional somatic
syndrome (FSS) characterised by patterns of persistent
bodily complaints for which a thorough diagnostic
workup does not reveal adequate explanatory structural
pathology [1]. IBS is one of the most prevalent gastro-
intestinal disorders in Western countries [2] and is re-
ported to frequently co-occur with other chronic and
functional diseases [3]. Similar to individuals with other
FSS, IBS patients who seek consultations utilise health
care services more frequently than non-IBS patients [4].
IBS causes a substantial economic burden. In two system-
atic reviews, total direct costs for IBS in the United States
and the United Kingdom are estimated between 348 USD
and 8750 USD per patient per year [5] with total annual
costs of 45.6 million pounds in the UK and 1.35 billion
USD in the USA [6]. Detailed insight into disease-specific
health care costs is critical because it co-determines the
societal impact of the disease, enables the assessment of
the cost-effectiveness of existing and new treatments, and
facilitates choices in treatment policy [7].
Societal costs for health care can be divided into sev-
eral categories: direct medical costs associated with diag-
nosis and treatment, indirect costs related to production
losses, and intangible costs related to the impact of the
disease on the patient’s quality of life [8].
Although guidelines suggest that in the absence of
alarm symptoms, the majority of IBS patients can be ad-
equately managed in primary care [9], there are substan-
tial differences in referral rates across Europe, ranging
from 10 % in the Netherlands [10] to 44 % in the UK
[5]. If disease-related medical costs for IBS management
substantially differ between primary and secondary care,
variation in referral rates will have important economic
consequences.
In the present study, we aimed to obtain insight into the
economic consequences of referral in IBS management by
comparing direct medical costs for IBS when patients are
diagnosed and treated in primary or secondary care. We
hypothesised that IBS management in secondary care is
more costly than that in primary care because of increased
co-morbidity, more intensive use of diagnostic tests and
frequent cross-referral to other specialists.
Methods
Design
We performed a retrospective case-control study using
reimbursement anonymised data from Achmea Health
Insurance, one of the largest health insurance companies
in the Netherlands, and anonymised routine care data
from the primary care database of the Julius Primary
Care Network (JPCN) of the University Medical Centre,
Utrecht. In the Netherlands all patients have an compul-
sory healthcare insurance. The use of the data was
approved by the research committees of both Achmea
and JPCN. Patients from the JPCN database were linked
to an Achmea policy holder by means of chance linking
based on date of birth, gender and postal-code. As the
data were delivered to the researchers anonymously, no
informed consent from the insurees was necessary.
Databases
The Achmea database contains reimbursement data for
more than one million patients. Achmea facilitates the
use of anonymised reimbursed healthcare consumption
data for scientific research under strict scientific and
ethical conditions. These data include medications, GP
and specialist consultations, diagnostic and therapeutic
procedures and hospital admissions. The reimbursement
for diagnostic and therapeutic procedures is standardised
using Diagnostic Treatment Codes (Dutch : DBC), which
include the first and last dates of treatment, the treating
specialist, the type of treatment and the diagnosis. Medi-
cations are registered in the database using anatomical
therapeutic codes (ATC) detailing the daily defined dos-
ages, the date and the costs of the medication reimburse-
ments. The GP contacts are registered using the date, type
of contact, International Classification for Primary Care
(ICPC) -coded diagnosis and reimbursed costs.
The JPCN database contains anonymous routine
healthcare data extracted from the electronic medical re-
cords (EMR) of 140 general practices with approximately
240.000 patients. The JPCN population represents an
average Dutch urban population. Approximately 50 % of
JPCN patients are insured by Achmea. In addition to the
demographic information, the database contains the
ICPC base diagnoses, diagnostic results, and ATC-based
prescription data.
Patient selection
We selected patients from 23 JPCN practices that accur-
ately registered the insurance companies used by their pa-
tients. Four groups were selected. The first group was
drawn from these 23 practices and consisted of all patients
who were diagnosed with IBS (ICPC-code) between 2006
and 2009 who were not referred to secondary care and
who were insured with Achmea healthcare. This group will
be referred to as primary care patients.
The second group consisted of all patients from the
Achmea database who were diagnosed with IBS by
hospital specialists (DBC-codes) between 2006 and 2009.
This group will be referred to as secondary care patients.
The IBS Diagnosis in primary and secondary care is gen-
erally made in accordance with the Rome- III criteria, in
the absence of red flag risk factors. The third and fourth
groups consisted of frequency matched on age- and
gender-matched control group without IBS, twice the
size of the first and second group, who were randomly
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drawn from the Achmea database: the third group
matched the primary care patients, the fourth group
matched the secondary care patients. Control-group
subjects all had one or more medical diagnoses regis-
tered by either GP or specialist, for any medical condi-
tion but IBS. Patients from the JPCN database were
linked to an Achmea policy holder based on their date
of birth, gender and postal code.
Study period
For secondary care, we allowed the diagnosis of IBS to
be made anywhere between 2006 and 2009. To ensure
that a primary care patient was not subsequently re-
ferred to a hospital, we excluded all the primary care pa-
tients who were diagnosed during the last year of study.
For the control subjects, the date of diagnosis of their
matched case was used as an index date.
Outcome
The primary outcomes were the direct medical costs for
diagnosis and management of IBS, generated in primary
and secondary care. The secondary outcomes were direct
total medical costs for co-morbid chronic, functional and
all other disorders of the IBS patients in the present study.
Cost specifications
The number of contacts with the GP were divided both
in primary and in secondary care for: consultations and
home visits during office hours, consultations and home
visits outside office hours, and repeat prescriptions.
Total costs for specialist care for IBS were calculated
and the specified costs for the following three diagnostic
groups: chronic disorders, all other functional disorders
and all other disorders, were calculated both for primary
and in secondary care .
For chronic disorders, the list of the ten most preva-
lent chronic diseases in the Netherlands was used
(RIVM 2010): diabetes mellitus, arthritis, coronary dis-
eases, noise- and old-age-related deafness, visual distur-
bances, asthma, contact eczema, chronic obstructive
pulmonary disease (COPD), stroke, and constitutional
eczema. Ten specialists were asked to select the DBC
codes that were used to register these disorders. For the
functional disorders, the same procedure was followed:
specialists on different clinical topics were asked to
determine which of the DBC codes concerned functional
disorders. A functional disorder was defined according
to the definition of Henningsen et al. [1]. The group of
all other disorders excluded all previously specified
groups, including psychiatric disorders (in the
Netherlands these were not registered using the same
system).
We included total medication costs and specified the
costs both for primary and in secondary care for the
following subgroups of medications associated with
functional (gut) disorders: laxatives , spasmolytics, anti-
depressants and hypnotics.
Analysis
For IBS patients diagnosed in primary and secondary
care as well as for their respective controls, the reim-
bursement data for IBS management and relevant co-
morbidity were extracted and the direct medical costs
were calculated; all observed years before and after the
diagnosis between 2006 and 2009 were analysed as sep-
arate observations. Total costs were divided into three
subgroups: GP costs, hospital or specialist costs and
medication reimbursement costs. For the cases and their
controls, we calculated the average annual costs before
and after IBS diagnosis.
Data analysis was performed using SAS version 9.2
(SAS Institute Inc., Cary, NC). We described the differ-
ences between primary and secondary care IBS patients
and their controls and tested the differences in mean
costs between primary and secondary care IBS patients




Among the 20.000 ACHMEA insured primary care per-
sons in the JCPN population we identified 326 patients di-
agnosed with IBS and only treated in primary care. From
the 1.000.000 Achmea insured persons we were able to se-
lect 9274 IBS patients diagnosed in secondary care. We in-
cluded 652 primary care and 18,548 secondary care non-
IBS patients as controls. For the percentages of females
and mean age, see Table 1. For a breakdown of the num-
ber of cases per year before and after IBS diagnosis, see
Table 1.
Table 1 Study population, number and characteristics
Primary care patients Primary care controls Secondary care patients Secondary care controls
Total number N 326 652 9274 18548
Female gender N / % 230 / 70 % 460 / 70 % 6506 / 70 % 13012 / 70 %
Patients with data before diagnosis N 133 266 5972 11944
Patients with data after diagnosis N 326 652 7538 15076
Age Average (SD) 49 (17) 49 (17) 53 (18) 53 (18)
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Nine primary care control patients and one primary
care IBS patient were excluded from the analysis because
their annual average healthcare costs exceeded five
standard deviations (SD) above the average.
Total annual health care costs before and after IBS
diagnosis
Mean total annual healthcare costs for primary care IBS
patients increased after the diagnosis by 486 Euro
(±3192) and for secondary care IBS patients by 2328
Euro (±5888). The difference in total cost increase be-
tween primary and secondary care patients was signifi-
cant (p < 0.01). We did not find a significant difference
in the total change in cost between the two control
groups (p = 0.26) (Table 2).
This increase was primarily explained by the increase in
hospital specialists’ costs and in medication costs. These
costs increased and remained high over each of the three
years after diagnosis. There was a slight increase in costs
for GP care for primary and secondary care patients,
whereas GP costs in the two control groups minimally
changed over time. The increase in costs was significantly
greater for secondary care patients compared to primary
care patients for medications, hospital specialist costs and
total costs, while there was no significant difference for
GP costs (Table 2).
Number of contacts with the general practitioner before
and after IBS diagnosis
The mean annual number of consultations and home
visits during office hours increased by 2 visits for pri-
mary care and 1 visits for secondary care IBS patients
after the IBS diagnosis (Table 3). For control patients
these numbers did not change. Consultations outside of
office hours and home visits increased only for second-
ary care IBS patients, whereas for controls there were no
consultations.
For primary and secondary care IBS patients the mean
annual number of repeat prescriptions increased by 2,
whereas for controls this remained at the same level
(Table 3).
Annual hospital specialist care costs before and after IBS
diagnosis
Mean overall costs for specialist care for secondary care
IBS patients rose by 1870 Euro (±5269) annually after
the IBS diagnosis was made. For primary care IBS pa-
tients this increase was 298 Euro (±2719). This differ-
ence between primary and secondary care patients was
significant (p < 0.01) (Table 2).
For secondary care IBS patients, the mean IBS specific,
annual specialists’ care costs increased with 427 Euro
(±572).
Mean annual costs for all other chronic disorders in-
creased with 100 Euro (±1299) for primary care IBS pa-
tients and with 282 Euro (±2337) for secondary care
patients The cost increase was significantly higher in
secondary care (p <0.01)
The difference in the increase of costs between primary
and secondary care patients was significant (p < 0.01)
(Table 4). These costs remained high over each of the
three years after diagnosis. The disease groups contribut-
ing to the cost increase were: angina pectoris, arthritis and
stroke in primary care patients and coronary diseases,
COPD, asthma and visual disturbances in secondary care
patients.
In both IBS patient groups, no substantial change in
costs related to all other functional disorders after the
diagnosis (-23 and +21 respectively) was found , though
this difference in the increase of costs between primary
and secondary care patients was significant (p < 0.01).
There was a considerable increase in the mean annual
costs for ‘all other disorders’ after IBS was diagnosed in
primary care patients (221 Euro (±2351)). These costs
also increased and remained high over each of the three
years after diagnosis. Highest increases were observed in
costs for hernia cicatricles, endometriosis and ileus. For
secondary care patients, the costs increased by 1139
Euro (±4395). The largest increases were observed for
diverticulosis, colon cancer, breast cancer and urinary
bladder tumours. This difference between primary and
secondary care patients was significant (p < 0.01)
(Table 4).
Medications before and after IBS diagnosis
The total costs for medications increased significantly by
426 Euro (±1587) in the group of secondary care pa-
tients and 164 Euro (±1177) for primary care patients
(Table 2). This difference between primary and second-
ary care patients was significant (p < 0.01). Table 5 shows
the change in medication costs in medication subgroups.
There was a sharp increase in antacid use among the
secondary care patients. The main contribution to the
medication costs increase came from ‘All other drugs’,
not related to any specific type of gastrointestinal medi-
cation. In this group, the difference in the cost increase
between primary and secondary care patients was sig-
nificant (p = 0.02).
Discussion
Summary of findings
Total health care costs for IBS patients increased sub-
stantially in the years after the diagnosis, 29 % for pri-
mary and 116 % for secondary care patients. In
secondary care this increase was primarily attributed to
costs for hospital specialists (+144 %) and medications
(+74 %). The most remarkable is that for all three kinds
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Table 2 Mean healthcare costs per patient per year (mean (SD) in Euro) (including both total and specific costs) for primary and secondary care IBS patients and matched















Mean dif (SD) P value
difference
GPs Primary care patients – 98 (103) 104 (103) 102 (103) 129 (120) 125 (130) 127 (127) 127 (125) 25 (121) 0.15
Secondary care patients 93 (90) 102 (97) 142 (119) 122 (110) 147 (165) 155 (158) 168 (181) 154 (166) 32 (146)
Primary care controls – 67 (67) 74 (94) 72 (87) 68 (78) 68 (75) 75 (95) 70 (81) −2 (82) 0.13
Secondary care controls 74 (88) 77 (99) 78 (98) 77 (97) 78 (96) 80 (95) 83 (96) 80 (2) 3 (96)
Hospital
specialistsa
Primary care patients – 1168 (2645) 1087 (2520) 1111 (2551) 1345 (2572) 1391 (2932) 1544 (2822) 1409 (2758) 298 (2719) <0.01×
Secondary care patients 1139 (3780) 1063 (2763) 1500 (3713) 1303 (3450) 3695 (6400) 2678 (6198) 2815 (5783) 3173 (6230) 1870 (5269)
Primary care controls – 591 (1812) 874 (2504) 792 (2325) 822 (2328) 1048 (2882) 1051 (2553) 955 (2585) 164 (2537) 0.16
Secondary care controls 1259 (4742) 1319 ± 4806) 1342 (6006) 1322 (5457) 1294 (8598) 1333 (4987) 1441 (5071) 1337 (5149) 15 (5277)
Medication Primary care patients – 401 (657) 448 (680) 434 (672) 522 (792) 580 (911) 751 (2087) 598 (1269) 164 (1177) <0.01×
Secondary care patients 477 (992) 545 (1143) 630 (1227) 579 (1169) 939 (1707) 999 (1797) 1163 (2087) 1005 (1822) 426 (1587)
Primary care controls – 398 (783) 481 (1360) 457 (1220) 449 (1252) 471 (1231) 490 (1435 466 (1291) 10 (1278) 0.97
Secondary care controls 525 (1398) 555 (1390) 558 (1452) 552 (1434) 561 (1597) 558 (1346) 561 (1304) 560 (1459) 8 (1445)
Totala Primary care patients – 1667 (2922) 1640 (2898) 1648 (2898) 1996 (2923) 2096 (3269) 2423 (3746) 2134 (3258) 486 (3192) <0.01×
Secondary care patients 1708 (4080) 1710 (3204) 2272 (4145) 2003 (3863) 4781 (7058) 3832 (6951) 4146 (6670) 4331 (6958) 2328 (5888)
Primary care controls – 1056 (2236) 1429 (3052) 1320 (2840) 1338 (2872) 1586 (3369) 1616 (3156) 1492 (3120) 171 (3068) 0.26
Secondary care controls 1858 (5295) 1950 (5376) 1978 (6501) 1951 (6002) 1933 (5893) 1971 (5490) 2086 (5558) 1976 (5692) 26 (5812)
aExcluding psychiatric care; ×, significant difference at alpha = 0.05































1. Consults and home visits during
office hours
Primary care patients – 6 (6) 7 (6) 6 (6) 8 (6) 8 (7) 8 (7) 8 (6) 2 (6)
Secondary care patients 6 (6) 7 (6) 10 (7) 8 (6) 9 (8) 9 (8) 10 (9) 9 (8) 1 (7)
Primary care controls – 4 (4) 5 (5) 4 (5) 4 (5) 4 (5) 5 (6) 4 (5) 0 (5)
Secondary care controls 5 (5) 5 (6) 5 (5) 5 (5) 5 (5) 5 (5) 5 (6) 5 (5) 0 (5)
2. Consults and home visits outside
office hours
Primary care patients – 0 (1) 0 (1) 0 (1) 0 (1) 0 (1) 0 (0) 0 (1) 0 (1)
Secondary care patients 0 (1) 0 (1) 0 (1) 0 (1) 1 (2) 1 (1) 1 (2) 1 (2) 0 (1)
Primary care controls – 0 (0) 0 (1) 0 (1) 0 (0) 0 (1) 0 (1) 0 (1) 0 (1)
Secondary care controls 0 (1) 0 (1) 0 (1) 0 (1) 0 (1) 0 (1) 0 (1) 0 (1) 0 (1)
3. Repeat prescriptions Primary care patients – 4 (6) 4 (5) 4 (6) 5 (7) 5 (7) 6 (8) 5 (7) 2 (7)
Secondary care patients 4 (6) 5 (6) 5 (6) 5 (6) 6 (7) 7 (8) 7 (8) 7 (7) 2 (7)
Primary care controls – 4 (6) 4 (6) 4 (6) 4 (5) 4 (5) 4 (6) 4 (5) 0 (5)
Secondary care controls 4 (5) 4 (6) 4 (6) 4 (6) 4 (6) 4 (6) 4 (6) 4 (6) 0 (6)












Table 4 Mean health care costs per patient per year for primary and secondary care IBS patients and their matched controls specified per year before and after diagnosis for





















Irritable bowel syndrome Primary care patients – 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) <0.01×
Secondary care patients 0 (0) 0 (0) 0 (0) 0 (0) 725 (866) 174 (520) 175 (468) 427 (745) 427 (572)
Primary care controls – 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0.99
Secondary care controls 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Chronic disorders Primary care patients – 332 (2074) 161 (543) 211 (1213) 289 (1151) 271 (1063) 407 (1819) 312 (1319) 100 (1299) <0.01×
Secondary care patients 318 (2373) 326 (1649) 379 (2017) 352 (1967) 600 (2659) 652 (2522) 684 (2407) 635 (2564) 282 (2337)
Primary care controls – 189 (1095) 236 (1295) 222 (1239) 212 (1137) 309 (1600) 413 (1924) 294 (1523) 72 (1473) 0.38
Secondary care controls 385 (2120) 398 (2314) 354 (1783) 373 (2021) 395 (2926) 379 (2187) 411 (2500) 393 (2611) 20 (2386)
Functional disorders Primary care patients – 21 (83) 67 (390) 54 (330) 30 (236) 41 (228) 17 (141) 31 (214) −23 (241) <0.01×
Secondary care patients 27 (242) 32 (262) 40 (289) 36 (274) 55 (346) 58 (478) 60 (365) 57 (399) 21 (353)
Primary care controls – 42 (440) 6 (57) 17 (242) 12 (134) 9 (96) 13 (112) 11 (117) −6 (149) 0.32
Secondary care controls 17 (214) 18 (218) 17 (182) 17 (199) 19 (223) 16 (151) 15 (136) 17 (185) 0 (191)
All other disordersa Primary care patients – 815 (1752) 860 (2382) 847 (2210) 1026 (2312) 1080 (2585) 1120 (2215) 1067 (2384) 221 (2351) <0.01×
Secondary care patients 794 (2863) 705 (2064) 1081 (2828) 915 (2616) 2315 (5429) 1794 (5322) 1896 (4882) 2054 (5292) 1139 (4395)
Primary care controls – 360 (954) 633 (2005) 553 (1767) 598 (1880) 730 (2234) 625 (1407) 650 (1911) 97 (1885) 0.26
Secondary care controls 857 (4107) 903 (3968) 971 (5630) 932 (4925) 880 (4197) 937 (4294) 1016 (4212) 927 (4233) 5 (4530)
T = −3 indicates three years before diagnosis, T = +1 one year after diagnosis and so forth













Table 5 Mean costs per patient per year for medication subgroups (mean euro (SD)) of primary and secondary care IBS patients and their matched controls specified per year





















1. Laxatives Primary care patients – 10 (38) 13 (41) 12 (40) 32 (105) 34 (107) 39 (123) 34 (110 23 (101) 0.72
Secondary care patients 9 (48) 9 (40) 18 (45) 14 (44) 46 (76) 33 (76) 36 (83) 39 (78) 25 (66)
Primary care controls – 1 (7) 3 (14) 2 (12) 3 (17) 2 (13) 4 (22) 3 (17) 1 (17)
Secondary care controls 5 (28) 5 (28) 5 (29) 5 (28) 5 (30) 6 (31) 6 (32) 6 (31) 0 (30)
2. Spasmolytics Primary care patients – 6 (24) 6 (24) 6 (24) 11 (31) 7 (25) 9 (33) 10 (29) 4 (28) 0.25
Secondary care patients 12 (70) 13 (75) 14 (76) 13 (75) 14 (73) 16 (77) 16 (76) 15 (75) 2 (75)
Primary care controls – 0 (0) 0 (2) 0 (2) 0 (6) 0 (3) 0 (3) 0 (4) 0 (4) 0.99
Secondary care controls 6 (52) 7 (53) 7 (52) 7 (52) 7 (52) 8 (53) 7 (47) 7 (51) 0 (52)
3. Anti-depressants Primary care patients – 7 (45) 10 (45) 9 (45) 15 (84) 17 (100) 20 (100) 16 (94) 7 (86) 0.66
Secondary care patients 2 (13) 2 (16) 5 (20) 3 (18) 9 (29) 8 (29) 9 (32) 8 (30) 5 (25)
Primary care controls – 2 (11) 4 (38) 4 (33) 8 (49) 10 (67) 8 (51) 9 (56) 5 (53) 0.02×
Secondary care controls 1 (9) 1 (9) 1 (10) 1 (10) 1 (9) 1 (9) 1 (11) 1 (10) 0 (10)
4. Antacids Primary care patients – 83 (229) 72 (181) 75 (196) 76 (184) 70 (155) 60 (138) 70 (164) −5 (171) <0.01×
Secondary care patients 47 (132) 56 (139) 70 (153) 62 (146) 117 (214) 113 (204) 115 (204) 115 (209) 54 (186)
Primary care controls – 26 (98) 22 (78) 23 (84) 27 (115) 30 (112) 29 (106) 28 (112) 5 (107) 0.16
Secondary care controls 36 (120) 37 (115) 36 (114) 36 (115) 36 (116) 35 (110) 33 (106) 35 (112) −1 (113)
5. Hypnotics Primary care patients – 12 (38) 8 (29) 10 (32) 8 (32) 7 (29) 4 (19) 7 (28) −3 (29) <0.01×
Secondary care patients 8 (30) 9 (33) 9 (34) 9 (33) 12 (41) 13 (42) 11 (40) 12 (41) 3 (38)
Primary care controls – 6 (23) 5 (22) 5 (22) 6 (27) 5 (25) 3 (19) 5 (25) 0 (24) 0.99
Controls to referred 6 (29) 6 ± 27) 6 (27) 6 (27) 6 (28) 6 (28) 5 (26) 5 (28) 0 (28)
6. Other ATC group N drugsa Primary care patients – 55 (139) 45 (152) 48 (148) 53 (144) 71 (234) 75 (274) 64 (214) 16 (203) 0.40
Secondary care patients 83 (309) 82 (305) 90 (357) 86 (334) 106 (397) 115 (410) 120 (412) 112 (404) 26 (377)
Primary care controls – 28 (79) 56 (311) 47 (265) 64 (456) 65 (359) 65 (352) 65 (400) 17 (378) 0.29
Secondary care controls 55 (246) 60 (292) 60 (319) 59 (300) 64 (354) 58 (306) 58 (293) 61 (327) 1 (316)
7. Other ATC group A drugsb Primary care patients – 44 (183) 42 (194) 43 (191) 40 (178) 41 (134) 46 (141) 42 (155) −1 (163) <0.01×
Secondary care patients 20 (97) 22 (95) 28 (125) 25 (112) 64 (223) 75 (257) 99 (304) 75 (253) 50 (207)
Primary care controls – 29 (97) 35 (146) 33 (133) 32 (170) 36 (195) 24 (120) 32 (169) −2 (163) 0.88












Table 5 Mean costs per patient per year for medication subgroups (mean euro (SD)) of primary and secondary care IBS patients and their matched controls specified per year
before and after diagnosis (Continued)
8. All other drugsc Primary care patients – 182 (321) 252 (454) 232 (419) 287 (508) 333 (649) 497 (1944) 354 (1085) 123 (992) 0.02×
Secondary care patients 296 (830) 352 (1009) 397 (1065) 367 (1015) 570 (1504) 627 (1565) 757 (1859) 627 (1604) 261 (1392)
Primary care controls – 306 (678) 356 (1263) 341 (1124) 308 (1082) 322 (1070) 356 (1320) 325 (1140) −17 (1137) 0.57
Secondary care controls 373 (1258) 393 (1235) 397 (1295) 392 (1270) 399 (1464) 401 (1202) 410 (1152) 402 (1320) 9 (1299)
T = −3 indicates three years before diagnosis, T = +1 one year after diagnosis and so forth
×Significant difference at alpha = 0.05
ATC group N drugs
aATC group N drugs: Drugs typically aimed at the neurological system, excluding Anti-depressants and Hypnotics
bATC group A drugs: Drugs typically aimed at the alimentary tract, excluding laxatives, spasmolytics and antacids












of medical costs these remain high all three years after
diagnosis.
The additional specialist-associated costs for the pri-
mary care IBS patients were primarily due to chronic
disorders other than IBS (nearly 50 %) and by other
disorders (25 %). This observation is consistent with the
results from a study by Levy et al. [11], in which the ma-
jority of the excess health care costs between IBS
patients and population controls was attributed to care
unrelated to lower GI problems. The increase in costs
related to hospital specialist care for secondary care pa-
tients is, for the most part, due to costs for other chronic
disorders (+80 %) and ‘all other disorders’ (+124 %). Pa-
tients with functional gastrointestinal diseases consult
their doctors more often for non-gastrointestinal com-
plaints [12] and for other somatic and psychiatric disor-
ders [3]. We hypothesise that gastroenterologists are
more likely to refer IBS patients to other hospital spe-
cialists than GPs, thus explaining the differences in in-
creased costs. In the Netherlands, as in many other
countries with a strong primary care, the GP as acts as
the ‘case manager ‘of the patient , coordinating the diag-
nostic and treatment process. The longitudinal relation
with the patient and the knowledge of medical history
and psychosocial system facilitates an integral approach
to IBS , and helps to prevent unnecessary referral and
diagnostic procedures. This benefits both disease out-
come, and patient’s quality of life and reduces health
care costs.
Comparison with similar studies
It is remarkable that in our study, the costs for other
functional disorders (e.g., fibromyalgia, fatigue and unex-
plained pain) in IBS patients are not very high, although
high rates of co-occurrence of IBS with other functional
diseases have been reported [3]. In the Netherlands, both
in primary and secondary care, only one diagnosis per
specialty can be designated per treatment. The general
practitioner and specialist may be inclined to select the
diagnosis with the highest reimbursement value as a re-
sult of this policy. Because the reimbursement value for
functional disorders is relatively low, this result might
lead to an under diagnosis.
The increase in antacid use after the IBS diagnosis in
secondary care may be explained by the fact that more
than in primary care , gastroenterologists are aware of
the overlap between IBS and upper gastrointestinal
symptoms. This results is frequent co-prescription of
antacids, H 2 blockers and PPI’s in patients diagnosed
with IBS.
Strengths and limitations
The extrapolated incidence of IBS in our study popula-
tion was 5. 4/1000/year, which is in line with the IBS
incidence reported for primary care in the Netherlands.
This indicates that the patients sample we extracted is
representative for primary care IBS patient group in the
Netherlands.
A strong point of this study is the long observation
period. Whereas the majority of previous studies have
gathered information for up to one year [7, 13–17], we
gathered total costs over four years. Because data from
the insurance company are based on reimbursement, the
dataset provide insight into valid medical costs and not
proxy costs calculated from medical file research or
questionnaire data.
The demographic characteristics of our IBS population
are notable. The Achmea population is slightly older than
the mean Dutch population. In the Netherlands, approxi-
mately 15 % of the population is 65 years or older; for the
Achmea population, this is 18 % [18]. In the studies of
Akehurst et al. [7], Creed et al. [13] and Hillillä et al. [16],
the mean ages of the studied populations were 47, 39 and
42 years, respectively. The mean age of our IBS population
(i.e. 49 for primary care; 53 for secondary care) is higher.
Total health care costs increase with age and decrease
with a higher educational level [19]. College-educated sub-
jects incur significantly lower health care costs through
their insurance program [19]. The Achmea population has
a lower educational level (as measured by the postal code)
compared to the average Dutch population.
Costs observed in the present study were highly skewed
towards the lower end of the cost spectrum, as reflected
in the high standard deviations relative to the average
costs. One might argue that the median values would be
more suitable for presenting numbers in highly skewed
distributions. However, we chose not to do so because in
healthcare, a small group of people are often responsible
for a large share of the costs. The medians might result in
values that are very low or even zero, underestimating the
actual financial burden of IBS on society.
Not all patients in our study had data available for the
year before the IBS diagnosis. Nevertheless, we calculated
averages for these patients for the period after the initial
diagnosis because the number of primary care patients
with IBS was low. One could argue that this observation
may have generated a bias because, theoretically, patients
for whom data are only available after diagnosis have dif-
ferent characteristics than those who were analysed both
in the years before and after diagnosis. To test this possi-
bility, we examined only the cases for whom data were
available before and after the diagnosis, and we did not ar-
rive at different conclusions.
Another limitation is the fact that although multidis-
ciplinary guidelines in the Netherlands recommend the
use of Rome criteria to diagnose IBS, we did not check
if the physicians in our study actually used these
criteria. Although this may have resulted in diagnostic
Flik et al. BMC Gastroenterology  (2015) 15:168 Page 10 of 11
uncertainty in some, we think that the diagnosis was
valid in the majority of IBS patients included.
One might argue that there is a difference in IBS symp-
tom severity and disease impact between patients attend-
ing primary and secondary care, which explains the bigger
increase in IBS costs in secondary care. We do not share
this viewpoint. A study by Smith et al. showed [20] no dif-
ference in IBS symptom severity between patients treated
in primary and secondary care. In addition, our results
demonstrate that the difference in costs between primary
and secondary care is not so much due to direct IBS re-
lated costs but due to costs for other disorders.
Conclusion
Health care costs substantially increase after the diagnosis
of IBS is made, and costs increase significantly more and
remain higher over the years for patients who are treated
in secondary care compared to patients treated by a GP.
IBS patients should be treated in primary-care where pos-
sible, not only because guidelines recommend this from a
quality of care viewpoint, but also to optimize use of
health care resources. Referral should be restricted to
those patients with alarm symptoms, with ill-matching
symptoms, or other cases of diagnostic uncertainty.
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